Information to authors
Plasma apolipoproteins A1/B and oxLDL levels in patients with COVID-19 as possible markers of the disease
SUMMARY. COVID-19 infection is associated with dyslipidemia and cardiovascular complications. The aim of the study was to determine the content of ApoA1, ApoB and oxidized low-density lipoproteins (oxLDL) in the plasma of patients (n = 81) with COVID-19, diabetes and cardio-vascular disease (CVD). ApoA1, ApoB and oxLDL were determined using enzyme-linked immunosorbent assay kits («Elabscience», USA). The measurements were performed at an optical wavelength of 450 nm. It was shown that the level of ApoA1 in the blood of patients with type 2 diabetes and, especially, with COVID-19 was significantly lower than in the blood of healthy people. Blood ApoA1 levels did not show a further decrease in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without concomitant diseases. It was found that the level of ApoB in the blood of patients with diabetes and, especially, with COVID-19 is significantly higher than in the blood of healthy people. Blood levels of ApoB and oxLDL are higher in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without comorbidities. Thus, levels of ApoA1, ApoB and oxLDL may be promising markers of COVID-19.
Key words: COVID-19, diabetes mellitus, cardiovascular diseases, apolipoprotein A1, apolipoprotein B, oxLDL
E-mail: pushkarev.vm gmail.com; svitlana.cherviakova gmail.com; endocrinology.kiev gmail.com; axolotle gmail.com; belchina_ ukr.net; kovzun.oi gmail.com; liubov_sokolova ukr.net
1. Begue, F., Tanaka, S., Mouktadi, Z., et al., Altered high-density lipoprotein composition and functions during severe COVID-19, Sci. Rep., 2021, vol. 11, no. 1, p. 2291. https://doi.org/10.1038/s41598-021-81638-1
2. Cochran, B.J., Ong, K.L., Manandhar, B., and Rye, K.A., High density lipoproteins and diabetes, Cells, 2021, vol. 10, no. 4, p. 850. https://doi.org/10.3390/cells10040850
3. Devaraj, S., Semaan, J.R., and Jialal, I., Biochemistry, Apolipoprotein B, in StatPearls, Treasure Island, FL: StatPearls Publ., 2020.
4. Dong, H., Chen, W., Wang, X., et al., Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study, Metab. Brain Dis., 2015, vol. 30, no. 6, pp. 1319–1330. https://doi.org/10.1007/s11011-015-9732-7
5. Feingold, K.R., The bidirectional link between HDL and COVID-19 infections, J. Lipid Res., 2021, vol. 62, p. 100067. https://doi.org/10.1016/j.jlr.2021.100067
6. Fogacci, F., Borghi, C., and Cicero, A.F.G., Misinterpreting data in lipidology in the era of COVID-19, J. Clin. Lipidol., 2020, vol. 14, no. 4, pp. 543–544. https://doi.org/10.1016/j.jacl.2020.07.004
7. Fritzen, A.M., Domingo-Espin, J., Lundsgaard, A.M., et al., ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKa2, Mol. Metab., 2020, vol. 35, p. 100949. https://doi.org/10.1016/j.molmet.2020.01.013
8. Gao, L., Zhang, Y., Wang, X., and Dong, H., Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study, BMC Endocrinol. Disord., 2021, vol. 21, no. 1, p. 59. https://doi.org/10.1186/s12902-021-00726-5
9. Inoue, Y., Okamoto, T., Honda, T., et al., Disruption in the balance between apolipoprotein A-I and mast cell chymase in chronic hypersensitivity pneumonitis, Immun. Inflamm. Dis., 2020, vol. 8, no. 4, pp. 659–671. https://doi.org/10.1002/iid3.355
10. Khatana, C., Saini, N.K., Chakrabarti, S., et al., Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis, Oxid. Med. Cell Longev., 2020, vol. 2020, p. 5245308. https://doi.org/10.1155/2020/5245308
11. Kocar, E., Rezen, T., and Rozman, D., Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2021, vol. 1866, no. 2, p. 158849. https://doi.org/10.1016/j.bbalip.2020.158849
12. Mao, Y., Xu, Y., and Lu, L., The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes, Medicine (Baltimore), 2017, vol. 96, no. 1, e5834. Erratum in: Medicine (Baltimore), vol. 96, no. 12, e6541. Erratum in: Medicine (Baltimore), vol. 96, no. 17, no. e6821.https://doi.org/10.1097/MD.0000000000005834
13. Retnakaran, R., Ye, C., Connelly, P.W., et al., Serum apoAl (apolipoprotein A-1), insulin resistance, and the risk of gestational diabetes mellitus in human pregnancy—brief report, Arterioscler. Thromb. Vasc. Biol., 2019, vol. 39, no. 10, pp. 2192–2197. https://doi.org/10.1161/ATVBAHA.119.313195
14. Rye, K.A., Barter, P.J., and Cochran, B.J., Apolipoprotein A-I interactions with insulin secretion and production, Curr. Opin. Lipidol., 2016, vol. 27, no. 1, pp. 8–13. https://doi.org/10.1097/M0L.0000000000000253
15. Sniderman, A.D., Thanassoulis, G., Glavinovic, T., et al., Apolipoprotein B particles and cardiovascular disease: a narrative review, JAMA Cardiol., 2019, vol. 4, no. 12, pp. 1287–1295. https://doi.org/10.1001/jamacardio.2019.3780
16. Sokolova, L., Pushkarev, V., Pushkarev, V., et al., Diabetes mellitus and atherosclerosis. The role of inflammatory processes in pathogenesis, Int. J. Endocrinol. (Ukraine), 2017, vol. 13, no. 7, pp. 486–498. https://doi.org/10.22141/2224-07220.127.116.117.115747
17. Sokolova, L.K., Risk factors and clinical and diagnostic aspects of cardiovascular pathology in patients with type 1 and 2 diabetes mellitus, Extended Abstract of Doctoral (Med.) Dissertation, Kyiv, Ukraine: Komisarenko State Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine, 2014.
18. Wei, X., Zeng, W., Su, J., et al., Hypolipidemia is associated with the severity of COVID-19, J. Clin. Lipidol., 2020, vol. 14, no. 3, pp. 297–304. https://doi.org/10.1016/j.jacl.2020.04.008
19. Yan, Y., Song, D., Wu, J., and Wang, J., Long noncoding RNAs link oxidized low-density lipoprotein with the inflammatory response of macrophages in atherogenesis, Front. Immunol., 2020, vol. 11, p. 24. https://doi.org/10.3389/fimmu.2020.00024
20. Yang, Y., Zhu, Z., Fan, L., et al., Low serum level of apolipoprotein A1 is an indicator of severity in patients with coronavirus disease 2019, Preprint, 2020. https://doi.org/10.21203/rs.3.rs-31251/v1
21. Zamanian, A.M., Arjmand, B., Zali, A., and Razzaghi, M., Introducing AP0A1 as a key protein in COVID-19 infection: a bioinformatics approach, Gastroenterol. Hepatol. Bed Bench, 2020, vol. 13, no. 4, pp. 367–373.
|Coded & Designed by Volodymyr Duplij||Modified 03.10.23|